BRAF inhibitor–associated ERK activation drives development of chronic lymphocytic leukemia

Patients with BRAFV(600E/K)-driven melanoma respond to the BRAF inhibitor vemurafenib due to subsequent deactivation of the proliferative RAS/RAF/MEK/ERK pathway. In BRAF WT cells and those with mutations that activate or result in high levels of the BRAF activator RAS, BRAF inhibition can lead to E...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Invest
Main Authors: Yaktapour, Niuscha, Meiss, Frank, Mastroianni, Justin, Zenz, Thorsten, Andrlova, Hana, Mathew, Nimitha R., Claus, Rainer, Hutter, Barbara, Fröhling, Stefan, Brors, Benedikt, Pfeifer, Dietmar, Pantic, Milena, Bartsch, Ingrid, Spehl, Timo S., Meyer, Philipp T., Duyster, Justus, Zirlik, Katja, Brummer, Tilman, Zeiser, Robert
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2014
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4347247/
https://ncbi.nlm.nih.gov/pubmed/25329694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI76539
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki